Acrux Limited (AU:ACR)
ASX:ACR
Want to see AU:ACR full AI Analyst Report?
Top Page
Acrux
(Sydney:ACR)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.02
▼(-25.00% Downside)
Action:Reiterated
Date:06/12/26
The score is primarily held down by weak financial performance (ongoing losses, negative cash flows, and high leverage). Technicals offer some support with the price above major moving averages, but momentum carries overbought risk. Valuation remains unattractive/unclear due to negative earnings and no dividend yield.
Positive Factors
Revenue Growth
Sustained double‑digit revenue growth in 2025 indicates improving commercial traction for licensed products. For a royalty/licensing model this durable top‑line expansion can translate into steadily rising recurring royalties and better leverage of fixed costs as partner sales scale.
Negative Factors
High Leverage
A very high debt-to-equity ratio materially raises financial risk: higher interest costs, refinancing exposure and reduced flexibility to fund development or support partners. Leverage constrains strategic optionality and increases the probability that external financing will be required within months.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained double‑digit revenue growth in 2025 indicates improving commercial traction for licensed products. For a royalty/licensing model this durable top‑line expansion can translate into steadily rising recurring royalties and better leverage of fixed costs as partner sales scale.
Read all positive factors
Acrux (ACR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.83M
Dividend YieldN/A
Average Volume (3M)120.95K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth250.37%
EPS Growth71.29%
CountryAU
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding522,284,360
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Acrux Business Overview & Revenue Model
Company Description
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other internatio...
How the Company Makes Money
Acrux primarily makes money through licensing arrangements for its topical pharmaceutical products and intellectual property. Under these arrangements, a commercial partner markets and sells the licensed product, and Acrux earns revenue via (a) ro...
Acrux Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.19M | 5.09M | 8.43M | 1.72M | 1.34M |
| Gross Profit | 1.19M | 1.13M | 1.95M | -4.65M | -7.59M |
| EBITDA | -5.17M | -8.06M | -2.79M | -12.29M | -15.59M |
| Net Income | -5.95M | -5.80M | -764.00K | -9.83M | -12.63M |
Balance Sheet | |||||
| Total Assets | 7.22M | 8.96M | 14.30M | 15.27M | 24.20M |
| Cash, Cash Equivalents and Short-Term Investments | 863.00K | 2.94M | 6.23M | 5.83M | 15.27M |
| Total Debt | 3.63M | 3.70M | 2.35M | 2.08M | 2.23M |
| Total Liabilities | 6.20M | 5.69M | 5.60M | 6.18M | 5.73M |
| Stockholders Equity | 1.02M | 3.28M | 8.70M | 9.09M | 18.47M |
Cash Flow | |||||
| Free Cash Flow | -5.48M | -4.58M | 584.00K | -9.28M | -11.52M |
| Operating Cash Flow | -5.47M | -4.30M | 703.00K | -8.82M | -11.41M |
| Investing Cash Flow | -5.00K | -276.00K | -119.00K | -465.00K | -102.00K |
| Financing Cash Flow | 3.39M | 1.29M | -183.00K | -155.00K | 17.58M |
Acrux Technical Analysis
Positive
0.02
Price Trends
0.01
Positive
0.01
Positive
0.01
Positive
Market Momentum
<0.01
Negative
57.21
Neutral
54.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACR, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.21 is Neutral, neither overbought nor oversold. The STOCH value of 54.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACR.
Acrux Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$519.41M | 15.32 | 13.29% | 0.38% | 5.17% | -16.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$292.55M | -90.75 | -15.96% | ― | 364.97% | 74.50% | |
46 Neutral | AU$7.83M | -2.62 | -211.88% | ― | 250.37% | 71.29% | |
46 Neutral | AU$12.98M | -1.99 | -218.76% | ― | 76.94% | 42.95% | |
45 Neutral | AU$60.15M | -0.49 | -131.13% | ― | 2086.71% | -116.20% | |
44 Neutral | AU$6.05M | -1.57 | -29.91% | ― | 82.28% | 13.33% |
* Healthcare Sector Average
AU:ACR
Acrux
0.02
>-0.01
-16.67%
AU:CUV
Clinuvel Pharmaceuticals
10.30
0.91
9.64%
AU:SPL
Starpharma Holdings Limited
0.70
0.61
708.14%
AU:TRP
Tissue Repair Ltd
0.10
-0.07
-41.18%
AU:CMB
Regeneus Ltd.
0.48
0.27
126.19%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.28
-92.67%
Acrux Corporate Events
Acrux Director Tim Oldham Increases Indirect Shareholding via Rights Exercise
Jun 2, 2026
Acrux Ltd has disclosed a change in the security holdings of director Tim Oldham, reflecting movements in both his direct and indirect interests. The update, lodged under listing rule obligations, details that Oldham holds interests through relate...
Acrux Director Increases Stake Through Exercise of Vested Rights
Jun 1, 2026
Acrux Limited has disclosed a significant change in director Ross Dobinson’s holdings following the exercise of vested unlisted rights granted in 2023, 2024 and 2025. The transaction increased his direct ownership to 10,746,351 ordinary shar...
Acrux Director Increases Shareholding Through Exercise of Equity Rights
Jun 1, 2026
Acrux Ltd has reported a change in the holdings of director Don Brumley, following the exercise of previously issued equity rights. Brumley exercised 1,433,360 vested unlisted rights granted in 2025 at no cash consideration, converting them into a...
Acrux Seeks ASX Quotation for Over 1.2 Million New Shares
Jun 1, 2026
Acrux Limited has applied for quotation on the ASX of 1,231,295 ordinary fully paid shares, to be issued on 2 June 2026. The new securities have been issued under an employee incentive scheme and will be quoted, indicating an expansion of the comp...
Acrux Performance Rights Lapse Trims Potential Share Dilution
Jun 1, 2026
Acrux Limited has announced the lapse of 100,000 performance rights, which have ceased because the conditions attached to those rights were not met or have become incapable of being satisfied as of 2 June 2026. The lapse slightly reduces the compa...
Acrux Details Milestone Structure for Australian Lenzetto Licensing Deal
May 29, 2026
Acrux Limited, a specialty pharma company listed on the ASX, develops and commercialises topically applied pharmaceutical products and has built a global footprint through licensing partnerships, particularly targeting the U.S. market. The company...
Acrux Expands Lenzetto Licensing to Australia in Deal Worth Up to AUD 5.4m
May 27, 2026
Acrux has amended its licensing agreement with long-term partner Gedeon Richter to cover the Australian market for its estradiol spray Lenzetto, a hormone replacement therapy for menopausal symptoms. Under the revised deal, Acrux will receive up t...
Acrux Plans Major Equity Issue to Bolster Capital Base
May 11, 2026
Acrux Limited has outlined plans for a fresh capital raise via a placement or similar securities issue, signalling continued use of equity funding to support its strategic and operational objectives. The proposed transaction includes up to 168,421...
Acrux Secures $1.6m Placement to Advance Female Testosterone Program
May 11, 2026
Acrux Limited has raised $1.6 million via a share placement to institutional and professional investors at $0.0095 per share, representing a discount to recent trading levels. Strong demand saw bids reach $2.6 million, leading to a $1.0 million sc...
Acrux Seeks Trading Halt Ahead of Proposed Capital Raising
May 7, 2026
Acrux Limited has requested an immediate trading halt for its ordinary shares on the ASX as it finalises the details of a proposed capital raising. The halt will remain in place until either the company releases its capital-raising announcement or...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.